Literature DB >> 24140182

Axitinib dose titration: what's the limiting factor?

Sebastiano Buti1, Camillo Porta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24140182     DOI： 10.1016/S1470-2045(13)70489-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.

Authors:  Jose A Karam; Catherine E Devine; Diana L Urbauer; Marisa Lozano; Tapati Maity; Kamran Ahrar; Pheroze Tamboli; Nizar M Tannir; Christopher G Wood
Journal:  Eur Urol       Date:  2014-02-07       Impact factor: 20.096

2.  Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma.

Authors:  Yoshiaki Yamamoto; Ryouichi Tsunedomi; Yusuke Fujita; Toru Otori; Mitsuyoshi Ohba; Yoshihisa Kawai; Hiroshi Hirata; Hiroaki Matsumoto; Jun Haginaka; Shigeo Suzuki; Rajvir Dahiya; Yoshihiko Hamamoto; Kenji Matsuyama; Shoichi Hazama; Hiroaki Nagano; Hideyasu Matsuyama
Journal:  Oncotarget       Date:  2018-03-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.